Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 103.66 +5.44 (5.54%)
Previous Close $98.22    52 Week High $118.49 
Open $99.79    52 Week Low $55.00 
Day High $103.71    P/E N/A 
Day Low $99.79    EPS $-0.56 
Volume 2,204,986       

Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1102.08 +3.51 (0.32%)
Previous Close $1098.57    52 Week High $88.16 
Open $1112.24    52 Week Low $67.88 
Day High $1119.45    P/E 255.11 
Day Low $1093.15    EPS $4.32 
Volume 3,014,837